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Underestimates the Benefits of TreatmentTo the Editor—In our article, ‘‘Mapping from disease-specific to
generic health-related quality of life scales: a common factor
model’’ [1], we propose a method for mapping mean treatment
effects reported in trials on one scale into mean treatment effects
on another scale. Our approach is based on a structural equation
model that, in its simplest form, partitions the variances of
responses to all scales into two components. One component is
that part of the test that responds to treatment, and the other
component is the remaining variance. We show that the true
mapping coefficient is the signed square root of the ratio of the
variances of the first component. We also point out that the
ordinary least squares (OLS) regression coefficient will invariably
underestimate the true mapping, because of the measurement
error inherent in the test instruments.
One of the motivations of our approach, which is not men-
tioned by Palta, is that mappings between mean treatment effects
should be both invertible and transitive. In other words, suppose
we have estimated a mapping b^Y-Q from disease-specific instru-
ment Y to generic scale Q, then when we observe an estimated
treatment effect d^Y in a trial, we would predict an effect
d^Q¼ b^Y-Q d^Y on the generic scale Q. Note that d^Y is usually an
unbiased and consistent estimate for the true treatment
effect. On the other hand, by the same token, if we observe d^Q
(also unbiased and consistent) in a trial, we would predict
d^Y¼ d^Q=b^Y-Q on scale Y. In other words, b^Q-Y¼1=b^Y-Q . We show
that mappings defined our way have this property. They must
also be transitive, which means that a mapping from X to Z must
be the product of a mapping from X to Y and a mapping from
Y to Z.
In her commentary on our article, Palta [2] takes issue with our
approach on two grounds. First, she claims that the mean treat-
ment effect is still ‘‘prone to measurement error,’’ and therefore
that the ‘‘correct conversion is [still] the true mappingmultiplied by
the reliability of the DSM.’’ She goes on to assert that the correct
mapping coefficient to map from X to Y, for either an individual
score or an estimated mean score, is the OLS regression, which is
the ‘‘true’’ mapping that would be obtained if there were no
measurement error in X, multiplied by the reliability of X. In our
notation, her proposed mapping coefficient is
bOLSX-Y¼bX-YrX
It is easy to see that this will end in a contradiction.
The mean treatment effects on scales X and Y have variances
that depend on sample size, n in each arm, the variance of the
true scores s2X, and its reliability:
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Under Palta’s proposed mapping, d^Y¼bOLSX-Y d^X¼bX-YrXd^X, we
would then obtainVarðd^YÞ¼ bOLSX-Y
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This gives us that b2X-Y¼s2Y=s2Xr2XrY . But by parity of argument,
we can also obtain that b2Y-X¼
s2X
s2YrXr
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Given that bX-Y¼1=bY-X, we end up with
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or s2Xs
2
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which is true only when both reliabilities are 1 (clearly s2X,s
2
Y are
not equal to zero).
The same argument can be made in a less technical and
perhaps more intuitive way. Imagine a trial of infinite size in
which the treatment effect is examined on three test instruments
X, Y, and Z. The true mappings are—by definition—the ratios of the
treatment effects dX,dY ,dZ on each scale. These ratios obviously
do have, and must have, the properties of transitivity and
invertability. If we imagine, instead, a trial of finite size, the
ratios of the estimates must still represent estimates of the
mappings, which are still transitive and invertible.
But the OLS mappings proposed by Palta, even if they were all
estimated from a single (and infinite sized) cohort study, can never
have these properties and must always underestimate the correct
mappings. Indeed, with her method, if one mapped from X to Y,
then back to X, one would not end up where one started.
Similarly, one could map from X to Y, and then from Y to Z, but
this would end up with a different estimate than mapping from X
to Z, even if one had used data from a single cohort study with
observations on all three instruments.
The second criticism is that the assumptions made by the
common factor model may not necessarily be correct for every
test, and Palta gives an example where this appears to be the
case. We would accept entirely that the common factor
model—at least as we have presented it—may be inadequate
for some data sets. This is noted in Lu and Brazier [1] where
possible extensions are suggested. This, however, does not
change the fundamental point that when observations are made
under measurement error, mappings between mean treatment
effects based on OLS regression are incorrect and invariably
underestimate the correct mapping. As a result, estimates of
the quality of life gain due to treatment based on such methods
are invariably underestimates.G. Lu, MSc
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